http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2209650-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f7b665fb8f15d0e2b0911539d39f8a2 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0356 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-072 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 |
filingDate | 2002-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75e650845c38a39c306265b0a2b5ccf7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3858414166b327a29510328780cfee5c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1044142f67c1ac2b2344a3faac8dbac3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_283906409e043692b97dbf4f01db9131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94f1948cfa641c0e298d28cd41b44c47 |
publicationDate | 2004-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-2209650-A1 |
titleOfInvention | NON-HUMAN MAMMERS DEFICIENT MUTANTS IN SIGMA RECEIVERS AND THEIR APPLICATIONS. |
abstract | Non-human mutant mammals deficient innSigma receivers and their applications.n n n \hbox{Sigma-1} pueden utilizarse comonmodelos para estudiar in vivo desórdenes del sistema nnervioso central, alteraciones de la memoria, condiciones de estrésny adicción a drogas, procesos de analgesia y neuroprotección. Losnmutantes deficientes en el receptor Sigma-2 puedennutilizarse para estudiar herramientas, diagnósticas o terapéuticas,n para combatir el cáncer y/o procesos degenerativos y/o para elndiseño de compuestos capaces de prevenir, reducir o aliviar lanpatología secundaria asociada a la administración de agentesnneurolépticos.The mutant non-human mammal genome, deficient in an endogenous Sigma receptor, contains a mutation comprising a disruption in a gene of an endogenous Sigma receptor, wherein said gene disruption results in a mutant that lacks detectable levels of endogenous Sigma receptor . The mutant can be used as a control animal for in vivo assays as well as a source of cells that can be used in in vitro assays . Deficient mutants in the receptor \ hbox {Sigma-1} They can be used as models to study in vivo central nervous system disorders, memory disorders, stress conditions and drug addiction, analgesia and neuroprotection processes. Mutants deficient in the Sigma-2 receptor can be used to study tools, diagnostic or therapeutic, to combat cancer and / or degenerative processes and / or to design compounds capable of preventing, reducing or alleviating secondary pathology associated with administration. of neuroleptic agents. |
priorityDate | 2002-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 528.